期刊文献+

基于不同体质量指数的2型糖尿病患者采用艾塞那肽治疗的临床效果

下载PDF
导出
摘要 目的探讨不同体质量指数的2型糖尿病患者采用艾塞那肽治疗的临床效果。方法将在该院接受治疗的60例2型糖尿病患者作为此次的研究对象,依据不同的体质量指数(BMI)将其分为甲组和乙组,甲组(19 kg/m2≤BMI<24kg/m2)共22例患者,乙组(BMI≥24 kg/m2)共38例患者,所有患者均进行艾塞那肽治疗,经过为期3个月的治疗之后比较糖化血红蛋白(Hb A1c)、餐后2小时血糖(2h PG)、空腹血糖(FPG)、血脂、血压以及体质量等多项指标的变化情况和不良反应发生情况。结果治疗后,两组患者在FPG、2h PG、Hb A1c、TG、BMI等指标上均较治疗之前有明显下降(P<0.05);乙组患者在BMI和体重等指标的下降幅度明显大于甲组(P<0.05);两组患者用药不良发应发生率对比差异无统计学意义(P>0.05)。结论对于超重或肥胖患者而言,艾塞那肽具有更好的治疗效果,在临床治疗中值得借鉴应用。
出处 《糖尿病新世界》 2016年第21期13-14,共2页 Diabetes New World Magazine
  • 相关文献

参考文献7

二级参考文献41

  • 1Gentilella K, Bianchi C, R.ossi A, et al. Exenatide: a review from pharmacology to clinical practice [J]. Diabetes Obes Metab, 2009, 11(6): 544-556.
  • 2Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glyeemic control and weight over 30 weeks in pa- tients with type 2 diabetes treated with metformin and a sulfonyl- urea [J]. Diabetes Care, 2005, 28(5): 1083-1091.
  • 3Gao Y, Yoon KH, Chuang L, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately con- trolled with metformin or mefformin and a sulphonylurea [J]. Diabe- tes Res Clin Praet, 2009, 83(1): 69-76.
  • 4Kolterman OG, Buse JB, Fineman MS,et al.Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glu- cose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2003, 88(7): 3082-3089.
  • 5Bcllo NT, Kemn MH, Ofeldt EM, ct al. Dose combinations of exert- din-4 and salmon calcitonin produce additive and synergistic reduc- tions in food intake in non-human primates [J]. Am J Physiol Intcgr Comp Physiol, 2010, 299(3): 945-952.
  • 6Defronzo RA, Ratner RE, Hart J, et al. Effects of excnatide(exea- din-4) on glycemic control and weight over 30 weeks in metfor- rain-treated patients with type 2 diabetes [J]. Diabetes Care, 2005, 28(5):1092-1100.
  • 7Gao Y, Yoon K H, Chuang L M, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or mefformin and a sulphonylurea [ J ]. Diabetes Res Clin Pract, 2009,83 ( 1 ) : 69 - 76.
  • 8Klonoff D C, Buse J B, Nielsen L L, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years [ J ]. Curr Med Res Opin, 2008,24( 1 ) : 275-286.
  • 9De Heer J, Hoist J J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1 [J]. Diabetes,2007,56(2) :438-443.
  • 10DeFronzo Pt A, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glueagon secretion, gastric emptying,and calorie intake:a randomized,cross-over study [J]. Curt Med Res Opin,2008,24 (10) : 2943 -2952.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部